Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide.
We previously described the enhanced cell uptake and transport of R.I-K(biotin)-Tat9, a large ( approximately 1500 Da) peptidic inhibitor of HIV-1 Tat protein, via SMVT, the intestinal biotin transporter. The aim of the present study was to investigate the feasibility of targeting biotinylated PEG-based conjugates to SMVT in order to enhance cell uptake and transport of Tat9. The 29 kDa peptide-loaded bioconjugate (PEG:(R.I-Cys-K(biotin)-Tat9)8) used in these studies contained eight copies of R.I-K(biotin)-Tat9 appended to PEG by means of a cysteine linkage. The absorptive transport of biotin-PEG-3400 (0.6-100 microM) and the bioconjugate (0.1-30 microM) was studied using Caco-2 cell monolayers. Inhibition of biotin-PEG-3400 by positive controls (biotin, biocytin, and desthiobiotin) was also determined. Uptake of these two compounds was also determined in CHO cells transfected with human SMVT (CHO/hSMVT) and control cells (CHO/pSPORT) over the concentration ranges of 0.05-12.5 microM and 0.003-30 microM, respectively. Nonbiotinylated forms of these two compounds, PEG-3350 and PEG:(R.I-Cys-K-Tat9)8, were used in the control studies. Biotin-PEG-3400 transport was found to be concentration-dependent and saturable in Caco-2 cells (K(m)=6.61 microM) and CHO/hSMVT cells (K(m)=1.26 microM). Transport/uptake was significantly inhibited by positive control substrates of SMVT. PEG:(R.I-Cys-K(biotin)Tat9)8 also showed saturable transport kinetics in Caco-2 cells (K(m)=6.13 microM) and CHO/hSMVT cells (K(m)=8.19 microM). Maximal uptake in molar equivalents of R.I-Cys-K(biotin)Tat9 was 5.7 times greater using the conjugate versus the biotinylated peptide alone. Transport of the nonbiotinylated forms was significantly lower (P<0.001) in all cases. The present results demonstrate that biotin-PEG-3400 and PEG:(R.I-Cys-K(biotin)Tat9)8 interact with human SMVT to enhance the cellular uptake and transport of these larger molecules and that targeted bioconjugates may have potential for enhancing the cellular uptake and transport of small peptide therapeutic agents.
Ramanathan
S
S
College of Pharmacy, Rutgers-The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Qiu
B
B
Pooyan
S
S
Zhang
G
G
Stein
S
S
Leibowitz
M J
MJ
Sinko
P J
PJ
D000818:Animals; D019380:Anti-HIV Agents / Q000378:metabolism / Q000493:pharmacokinetics; D001710:Biotin / Q000031:analogs & derivatives* / Q000235:genetics / Q000493:pharmacokinetics; D016466:CHO Cells; D018938:Caco-2 Cells; D002352:Carrier Proteins / Q000235:genetics; D006224:Cricetinae; D015696:Gene Products, tat / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000493:pharmacokinetics*; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000493:pharmacokinetics*; D011092:Polyethylene Glycols / Q000493:pharmacokinetics*; D021381:Protein Transport / Q000235:genetics; D013501:Surface-Active Agents / Q000493:pharmacokinetics*; D027981:Symporters; D054322:tat Gene Products, Human Immunodeficiency Virus
D019380:Anti-HIV Agents; D002352:Carrier Proteins; D015696:Gene Products, tat; D008562:Membrane Glycoproteins; D010446:Peptide Fragments; D013501:Surface-Active Agents; D027981:Symporters; C118267:Tat9-C-biotin; C119981:biotin transporter; D054322:tat Gene Products, Human Immunodeficiency Virus; C415751:tat peptide (1-9), Human immunodeficiency virus 1; D011092:Polyethylene Glycols; D001710:Biotin